Wealthcare Advisory Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealthcare Advisory Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,438	Closed	-$220K	–	2099
2021 Q1	$220K	Buy	+1,438	New	+$222K	0.02%	458
2020 Q2	–	Sell	-23	Closed	-$2K	–	1503
2020 Q1	$2K	Buy	23 +9	+64%	+$883	﹤0.01%	1345
2019 Q4	$2K	Hold	14	–	–	﹤0.01%	1297
2019 Q3	$1K	Hold	14	–	–	﹤0.01%	1323
2019 Q2	$2K	Hold	14	–	–	﹤0.01%	1220
2019 Q1	$2K	Hold	14	–	–	﹤0.01%	1125
2018 Q4	$1K	Hold	14	–	–	﹤0.01%	1181
2018 Q3	$2K	Hold	14	–	–	﹤0.01%	1147
2018 Q2	$2K	Hold	14	–	–	﹤0.01%	1149
2018 Q1	$2K	Sell	14 -3	-18%	-$359	﹤0.01%	986
2017 Q4	$2K	Buy	17 +3	+21%	+$365	﹤0.01%	947
2017 Q3	$2K	Buy	+14	New	+$1.9K	﹤0.01%	787

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Wealthcare Advisory Partners's ALXN Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 1,438 shares — an estimated $220K sold.

Wealthcare Advisory Partners first reported a position in ALXN in Q3 2017 and held it in 12 quarters. The position peaked at $220K in Q1 2021. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 1,438 Alexion Pharmaceuticals shares in Q2 2021, an estimated $220K.
Wealthcare Advisory Partners first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Wealthcare Advisory Partners's Alexion Pharmaceuticals position peaked at $220K in Q1 2021.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.